StockWatch
·

Godrej Agrovet Ltd Q2 FY27 Results

GODREJAGROQ2 FY27 Results
Filing
Result:Steady· Market: Flat#Margin squeeze#Cost led

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue3.0K4.9%16.6%
Total Income3.0K5.1%17.1%
Expenditure2.9K6.8%17.8%
PBT130.6922.4%4.9%
Net Profit102.7519.9%21.8%
OPM6.67%1.74pp1.64pp
NPM3.41%1.06pp0.13pp
EPS5.9914.3%24.5%
View full financials

Consolidated PAT grew only because finance costs and tax fell, while core segment PBIT was down 3.2% YoY and OPM compressed to 6.7% from 8.3%, so despite healthy revenue growth the quarter is in-line/ordinary rather than a quality beat.

GODREJAGRO · Q2 FY27 · THE VERDICT

Double-digit growth masks margin squeeze; structural recovery deferred to later innings

Q2 revenue surged 16.7% YoY to ₹2,995 Cr, PAT up 21.8% to ₹102.8 Cr. But profits collapsed 19.9% quarter-on-quarter, and operating margins compressed to 6.7%. The gap between headline growth and near-term execution is now the real story.

12 Nov 2026 · 6 min read
Revenue

₹2,995 Cr

+16.7% YoY (+4.9% QoQ)

PAT

₹102.8 Cr

+21.8% YoY (-19.9% QoQ)

OPM

6.7%

compressed from prior ~7.4%

EBITDA margin

7.4%

stable; ₹222 Cr absolute

On the headline, Q2 looks strong: revenue up 16.7% year-over-year, PAT up 21.8%. Dig into the sequence, though, and the real story surfaces — profits fell 19.9% quarter-on-quarter, and operating margins compressed to 6.7%, their lowest in recent quarters. This is the gap that matters. Godrej is delivering double-digit revenue growth on track for full-year guidance, but the quarter-to-quarter profit decline and margin squeeze signal that the structural tailwinds (Oil Palm capex, Foods B2C, Animal Nutrition premiumization) have not yet offset the near-term headwinds (El Niño agchem weakness, dairy input cost inflation, Astec enterprise demand softness).

The quarter in context: where profit came from

H1 FY27 consolidated revenue stands at ₹5,847 Cr (+13% YoY), tracking towards the full-year double-digit guidance. Q2 itself drove ₹2,995 Cr (+4.9% QoQ), a seasonal slowdown but sequentially offset by strong Oil Palm (+28% revenue, +14% FFB volume) and Animal Nutrition (+14% revenue, +32% profit growth). The strength came from premiumization — cattle feed and layer feed surged; broiler feed was deliberately de-prioritized for margin. Foods B2C delivered 50% growth, a structural acceleration with salience now 38% of the business (vs. 25% prior trajectory).

But the margin story inverted. Operating profit margin at 6.7% (₹202 Cr EBIT on ₹2,995 Cr revenue) fell from the prior range of ~7.4%, driven by three headwinds: elevated milk procurement and feed costs in Dairy (revenue +6%, profit down due to input inflation), El Niño-driven weakness in Crop Care (revenue on lower base, profit declined), and Astec LifeSciences enterprise demand softness (CDMO offset but not fully compensating). EBITDA held at 7.4% (₹222 Cr), but the downstream operating leverage collapsed — a sign that margin relief awaits downstream (Astec CDMO scale, Crop Care new product ramp, Oil Palm capex full commissioning).

Claims vs. what holds up

Management's core claims validated against delivered results and guidance track record.

Revenue grew 16.7% YoY to ₹2,995 Cr; PAT up 21.8% to ₹103 Cr

Verified: actual revenue ₹2,995 Cr (+16.7% YoY), PAT ₹102.8 Cr (+21.8% YoY). H1 consolidated ₹5,847 Cr, +13% YoY.

Supported

Double-digit consolidated revenue growth guidance for FY27 on track

H1 +13% YoY supports full-year double-digit target. Q2 +16.7% and +4.9% QoQ suggests continued momentum, though near-term volatility evident.

Supported

Oil Palm FFB volume +14% in extreme weather; OER recovery post-cyclone

OER 18.9% Q2 vs 19.8% target (miss); recovery visible in Oct ahead of prior year. FFB +14% confirmed. Annual target 19.7% stated as achievable.

Supported

Oil Palm integrated capex fully online by Q4 FY27; 2% EBITDA margin accretion midterm

CPKO refinery + mill + biogas came online Sept 1 (first phase only, 30 days in Q2). Hydrogenation/fractionation Dec. Full impact Q4 onwards. 2% accretion guidance for 2–4 year horizon post-full scale.

On track, but phased

Foods B2C 50% growth; structural channel shift underway

Verified: B2C growth 50% YoY, salience 38% vs prior 25%. Frozen chicken, momos, nuggets scaling. 25% of Foods business from new products launched <1yr.

Supported

Animal Nutrition premiumization delivering strong profit growth

Revenue +14%, segment profit +32% YoY. Cattle feed +8%, layer feed 100%+ growth. Broiler strategically de-prioritized.

Supported

Crop Care recovery decision by Q2-end (prior Q1 call)

No explicit recovery decision mentioned. Acknowledged as 'tough' quarter; new product pipeline (Ashitaka, Takaib, Ghassanash) rolling out Q4 onwards. Recovery deferred to structural plan (7 crop segments by FY2030).

Overstated / Deferred

Astec CDMO 20%+ growth on track (prior call)

20%+ target not reaffirmed on Q2 call. Enterprise demand weak in Brazil/US; CDMO offset noted but tone cautious. 90% inquiry-to-R&D conversion; ~15 products in pipeline.

Implicitly downgraded

What changed on this call

Foods B2C acceleration: Salience jumped from prior 25% trajectory to 38%, a half-year leap. Growth 50% YoY signals this is now material, not experimental. Management flagged new categories (momos, nuggets) and quick-commerce channels. Oil Palm capex tangible: First phase (CPKO refinery + mill + biogas) went live Sept 1; second phase (hydrogenation/fractionation) commissions Dec. Financial impact Q4 FY27 onwards, scaling FY28. Crop Care recovery pushed: Q1 call promised a 'recovery decision by Q2-end.' Q2 call offered no signal, only a structural diversification plan (7 crop segments by FY2030) and new product pipeline ramping Q4. Near-term remains under pressure. Astec guidance implicit downgrade: Prior 20%+ growth absent from Q2 call. Enterprise demand in Brazil/US acknowledged as 'challenging'; management pivoted to long-run partnership quality and CDMO transformation (50–55% target midterm) rather than near-term growth. Dairy margin outlook extended: Input cost inflation (milk, feed, packaging, logistics) flagged as structural. Margin recovery via premiumization and GTM revamp, but timeline extended to 2–3 quarters post-monsoon, not near-term.

The bull-bear ledger

Positive factors
  • Double-digit revenue growth on track; H1 +13%, Q2 +16.7%

  • Oil Palm FFB +14% YoY in extreme weather; capex first phase live

  • Animal Nutrition premiumization yielding 32% profit growth; thesis working

  • Foods B2C acceleration (50% growth, 38% salience); new products gaining traction

  • Management candid on headwinds (El Niño, agchem, margin pressure)

  • Working capital improved to 21 days from 32 days YoY

Negative factors
  • Q2 PAT -19.9% QoQ (₹102.8 Cr vs ~₹128 Cr Q1); near-term profit trend risky

  • OPM 6.7% compressed from prior ~7.4%; below range despite strong YoY growth

  • Crop Care recovery deferred; prior 'Q2-end decision' now structural plan to FY30

  • Dairy margin lag persisting; 6% revenue growth vs rising input costs

  • Astec 20%+ guidance not reaffirmed; enterprise demand soft in Brazil, US

  • El Niño recovery timing uncertain; OER at 18.9% vs 19.8% target

Risks ranked by how much they should concern a holder.

QoQ PAT decline (-19.9%): profit volatility

High

Q2 ₹102.8 Cr vs Q1 implied ~₹128 Cr signals near-term earnings instability. If H2 doesn't recover by Q4, FY27 PAT target will miss and damage guidance credibility.

OPM compression (6.7% vs prior ~7.4%): structural margin breakdown

High

Margin decline despite strong revenue growth suggests cost inflation (dairy, feed, packaging) is structural. If Oil Palm capex and Crop Care new products don't deliver accretion in H2, margins stay depressed into FY28, capping valuation.

Crop Care recovery deferred: guidance credibility

Medium

Q1 call promised recovery decision by Q2-end; Q2 deferred it to FY30 structural plan. Loses near-term credibility. If new products (Ashitaka, Takaib, Ghassanash) don't commercialize on schedule, Crop Care remains a drag through FY28.

Dairy margin lag: earnings headwind

Medium

6% revenue growth insufficient vs milk procurement and feed cost inflation. Value-added products 49% of portfolio but margin still under pressure. If premiumization doesn't gain traction in H2, dairy profit remains a drag.

Astec enterprise demand weak: growth miss

Medium

Brazil and US market toughness acknowledged. Prior 20%+ guidance absent from Q2 call. If R&D conversion pace and partnership commercialization don't accelerate in FY28, Astec remains a headwind to group earnings.

El Niño recovery timing uncertain: demand and commodity pressure

Medium

OER at 18.9% vs 19.8% target suggests recovery slower than expected. If El Niño persists into H2, OER and Crop Care demand remain under pressure; margin recovery pushed to FY28.

How the street is positioned

The stock is trading at ₹586.2, down 33.14% from its all-time high and 15.83% above its 52-week low. More tellingly, it sits below its SMA20 (₹601.33), SMA50 (₹631.17), and SMA200 (₹591.53) — a weak technical setup despite double-digit fundamental revenue growth. The RSI at 44 (neutral) suggests no oversold bounce imminent; the drawdown is pricing in persistent near-term execution risk. Ownership is largely stable: FII at 6.48% (vs 6.32% prior Q, +16 bps), DII at 5.28% (down from 5.86%), promoters at 67.74% (unchanged). The FII uptick is marginal and contradicts the price weakness — institutions are watching, not adding aggressively. This suggests a 'wait and see' posture on whether Q3 margins recover and Crop Care new products gain traction. The valuation disconnect — a company delivering 16.7% revenue growth and 21.8% PAT growth YoY now trading 33% below ATH — is a warning flag rather than a bargain. It signals the market has priced in either (1) sustained near-term margin depression, (2) disappointment on Crop Care/Astec recovery timelines, or (3) macro weakness in agchem/dairy/oil palm. Until one of those resolves positively, the downward bias likely persists.

The debate

What to watch next quarter
  • 1 · Oil Palm capex second phase impact (Dec commissioning)

    Verify whether phase two delivers incremental margin lift in Q3. If capex on time and EBIT margin expands back to 7.2–7.4%, the bull case gains credibility.

  • 2 · Crop Care new product commercialization

    Watch for revenue contribution from new launches (Ashitaka, Takaib, Ghassanash) and evidence of market traction. Q3 should show early-stage contribution; full impact FY28. Silence means recovery remains deferred.

  • 3 · Dairy margin stabilization; input cost inflation trajectory

    Q3 will reveal whether milk procurement, feed, packaging costs are stabilizing post-monsoon or remaining elevated. If stabilizing, premiumization gains will compound.

  • 4 · El Niño recovery confirmation; OER trajectory to 19%+

    Management said Oct OER was ahead of prior year; Q3 will confirm if recovery is sustained. If OER stabilizes at 19%+, Oil Palm profit recovery is on track and earnings confidence improves.

  • 5 · FY27 full-year PAT guidance tone: maintained, raised, or quietly managed down

    If management reaffirms double-digit PAT growth despite Q2 QoQ decline, the Street will ask for updated trajectory and Q3–Q4 guidance. If tone becomes cautious, expect 10–15% repricing down.

Q2 FY27 is steady execution on the revenue front — double-digit growth on track — but not a step-change for profit. The company is managing a transition: near-term headwinds (El Niño, agchem weakness, dairy cost inflation, Astec softness) are offsetting near-term margin recovery. The structural tailwinds (Oil Palm capex, Foods B2C, Animal Nutrition premiumization) are real and material, but H2 commissioning and commercialization timelines matter. Management is candid and positioned honestly; the stock's 33% drawdown from ATH is fair pricing of execution risk, not a clearance.

The number to track from here is operating margin trend. If Q3 OPM stabilizes and reverses toward 7.2%+, the bull case gains traction and the stock rerates. If it stays at 6.7% or dips further, the bear case (margin structure broken, recovery deferred to FY28) will dominate. That's the Q3 test.

Informational and educational content only. Not investment advice.